文献速递药物不良反应与药物警戒

21世纪风险管理:现状与未来需求

Risk Management for the 21st Century: Current Status and Future Needs.
PubMed 文献 · Drug Saf · 2021-02-09

本文阐述在ICH E2E和CIOMS VI指南推动下,药物全生命周期药物警戒与获益-风险管理更主动一致;近年风险最小化措施(RMMs)在设计、实施、传播和效果评估方面取得进展,但仍存挑战,呼吁全球在术语定义、方法学应用和最佳实践等方面协调统一。

要点

  • ICH E2E与CIOMS VI指南提升了药物全生命周期风险管理的主动性和一致性。
  • RMMs在设计、实施、传播及真实世界效果评估方面已有科学进展。
  • 需全球协调统一术语定义、稳健方法学应用及RMMs最佳实践。

核心结论

  • 风险最小化领域近年已有进展,但仍需全球协调统一术语、方法学和最佳实践。

研究设计与样本

  • 本文为综述性文章,描述RMMs设计、实施、传播和评估的进展,并引用全球案例说明循证方法如何指导RMMs开发。

主要发现

  • ICH E2E指南和CIOMS工作组VI指南的全球采纳使药物全生命周期药物警戒和获益-风险管理更主动、更一致。
  • 这些指南发布后,RMMs的设计、实施、传播及在真实世界医疗环境中效果评估的科学与实践已有重要进展。
  • 文章在考虑当地医疗系统政策和国家立法的同时,指出当前挑战并给出可能解决方案。

临床怎么用

  • 临床可参考RMMs的循证设计、实施、传播和效果评估方法,并结合本地医疗系统政策与国家立法应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Global adoption of risk management principles outlined in the International Conference on Harmonisation (ICH) E2E guideline and the Council for International Organizations of Medical Sciences (CIOMS) Working Group VI guidance introduced greater proactivity and consistency into the practice of pharmacovigilance and benefit-risk management throughout the lifecycle of a drug. However, following the release of these guidelines there have been important advances in the science and practice of risk minimisation itself, especially in terms of how risk minimisation measures (RMMs) are designed, implemented, disseminated and evaluated for effectiveness in real-world healthcare settings. In this article, we describe how the field of design, implementation, dissemination and evaluation of RMMs has advanced in recent years while highlighting current areas of challenge and possible solutions. Where possible we cite global examples to demonstrate how evidence-based approaches have informed the development of RMMs. In this context, while taking into consideration local healthcare system policies and national legislations, we conclude with a call for a global effort to harmonise certain areas that focus on, but are not limited to, standardising certain terms and definitions, consistent application of robust methodologies, and outline of best practices for risk minimisation design, implementation, and dissemination.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Mouchantaf R, Auth D, Moride Y, et al. Risk Management for the 21st Century: Current Status and Future Needs. Drug Saf. 2021. PMID: 33565024. doi:10.1007/s40264-020-01033-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。